Differentiation of Malignant and Benign Cardiac Tumors Using 18F-FDG PET/CT
Open Access
- 10 May 2012
- journal article
- Published by Society of Nuclear Medicine in Journal of Nuclear Medicine
- Vol. 53 (6), 856-863
- https://doi.org/10.2967/jnumed.111.095364
Abstract
In the diagnostic algorithm of cardiac tumors, the noninvasive determination of malignancy and metastatic spread is of major interest to stratify patients and to select and monitor therapies. In the diagnostic work-up, morphologic imaging modalities such as echocardiography or magnetic resonance tomography offer information on, for example, size, invasiveness, and vascularization. However, preoperative assessment of malignancy may be unsatisfactory. The aim of this study was to evaluate the diagnostic value of 18F-FDG PET and the incremental diagnostic value of an optimized CT score in this clinical scenario. Methods: 18F-FDG PET/CT scans (whole-body imaging with low-dose CT) of 24 consecutive patients with newly diagnosed cardiac tumors were analyzed (11 men, 13 women; mean age ± SD, 59 ± 13 y). The maximum standardized uptake values (SUVmax) of the tumors were measured. Patients were divided into 2 groups: benign cardiac tumors (n = 7) and malignant cardiac tumors (n = 17) (cardiac primaries [n = 8] and metastases [n = 9]). SUVmax was compared between the 2 groups. Results were compared with contrast-enhanced CT, using standardized criteria of malignancy. Histology served as ground truth. Results: Mean SUVmax was 2.8 ± 0.6 in benign cardiac tumors and significantly higher both in malignant primary and in secondary cardiac tumors (8.0 ± 2.1 and 10.8 ± 4.9, P < 0.01). Malignancy was determined with a sensitivity of 100% and specificity of 86% (accuracy, 96%), after a cutoff with high sensitivity (SUVmax of 3.5) was chosen to avoid false-negatives. Morphologic imaging reached a sensitivity of 82% and a specificity of 86% (accuracy, 83%). Both false-positive and false-negative decisions in morphology could be corrected in all but 1 case using a metabolic threshold with an SUVmax of 3.5. In addition, extracardiac tumor manifestations were detected in 4 patients by whole-body 18F-FDG PET/CT. Conclusion: 18F-FDG PET/CT can aid the noninvasive preoperative determination of malignancy and may be helpful in detecting metastases of malignant cardiac tumors.This publication has 33 references indexed in Scilit:
- Characterization and Management of Cardiac TumorsSeminars in Cardiothoracic and Vascular Anesthesia, 2010
- MRI and CT appearances of cardiac tumours in adultsClinical Radiology, 2009
- Assessing Tumor Response to TherapyJournal of Nuclear Medicine, 2009
- Cardiac metastasesJournal of Clinical Pathology, 2007
- Positron Emission Tomography As an Imaging BiomarkerJournal of Clinical Oncology, 2006
- Usefulness of magnetic resonance imaging of cardiac and paracardiac massesThe American Journal of Cardiology, 2003
- Metastatic Involvement of the Heart and Pericardium: CT and MR ImagingRadioGraphics, 2001
- CT and MR Imaging of Benign Primary Cardiac Neoplasms with Echocardiographic CorrelationRadioGraphics, 2000
- CT and MR Imaging of Primary Cardiac MalignanciesRadioGraphics, 1999
- Cardiac MyxomasThe New England Journal of Medicine, 1995